ArticleTissue engineering. Part A2021
Bioprinting on Live Tissue for Investigating Cancer Cell Dynamics.
Article in Tissue engineering. Part A, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Parasite in cancer therapy: molecular mechanisms and translational potential.Frontiers in immunology · 2026Review
- 3D Bioprinting and Artificial Intelligence for Tumor Microenvironment Modeling: A Scoping Review of Models, Methods, and Integration Pathways.Molecular pharmaceutics · 2025Article
- Modeling intratumor heterogeneity in breast cancer.Biofabrication · 2024Review
- Review
- 3D bioprinting and the revolution in experimental cancer model systems-A review of developing new models and experiences withPathology oncology research : POR · 2023Review
- 3D printing of bone and cartilage with polymer materials.Frontiers in pharmacology · 2022Review
- A Challenge for Engineering Biomimetic Microvascular Models: How do we Incorporate the Physiology?Frontiers in bioengineering and biotechnology · 2022Review
- 3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs.Cancers · 2021Review
- Review
- Cancer Cell Direct Bioprinting: A Focused Review.Micromachines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
A challenge in cancer research is the lack of physiologically responsive
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.